Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

"Gout can affect other joints. It may also cause “tophi” to develop (hard swellings around joints and the ears). Gout typically occurs in bouts or attacks, before settling with treatment and ...

The present study quantifies the impact of the presence of tophi and frequency of acute gout attacks on health-related quality of life (HRQOL), productivity, and healthcare resource utilization.

Surgical removal of the intradural lesion followed by pathological examination confirmed gouty tophi. The postoperative recovery was good, and the patient experienced substantial relief from pain and ...